Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

P. R. Bargo, Steven Jacques

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

Original languageEnglish (US)
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
EditorsD.D. Duncan, S.L. Jacques, P.C. Johnson
Pages50-56
Number of pages7
Volume4257
DOIs
StatePublished - 2001
EventLaser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical - San Jose, CA, United States
Duration: Jan 21 2001Jan 24 2001

Other

OtherLaser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical
CountryUnited States
CitySan Jose, CA
Period1/21/011/24/01

Fingerprint

Photosensitizers
drugs
penetration
cancer
Catheters
Tissue
reflectance
body weight
lungs
Optical fibers
optical fibers
Fluorescence
fluorescence
fibers
Fibers

Keywords

  • Dosimetry
  • Fluorescence
  • Optics
  • PDT
  • Photodynamictherapy
  • Reflectance

ASJC Scopus subject areas

  • Electrical and Electronic Engineering
  • Condensed Matter Physics

Cite this

Bargo, P. R., & Jacques, S. (2001). Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT. In D. D. Duncan, S. L. Jacques, & P. C. Johnson (Eds.), Proceedings of SPIE - The International Society for Optical Engineering (Vol. 4257, pp. 50-56) https://doi.org/10.1117/12.434744

Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT. / Bargo, P. R.; Jacques, Steven.

Proceedings of SPIE - The International Society for Optical Engineering. ed. / D.D. Duncan; S.L. Jacques; P.C. Johnson. Vol. 4257 2001. p. 50-56.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bargo, PR & Jacques, S 2001, Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT. in DD Duncan, SL Jacques & PC Johnson (eds), Proceedings of SPIE - The International Society for Optical Engineering. vol. 4257, pp. 50-56, Laser-Tissue Interaction XII: Photochemical, Photothermal, and Photomechanical, San Jose, CA, United States, 1/21/01. https://doi.org/10.1117/12.434744
Bargo PR, Jacques S. Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT. In Duncan DD, Jacques SL, Johnson PC, editors, Proceedings of SPIE - The International Society for Optical Engineering. Vol. 4257. 2001. p. 50-56 https://doi.org/10.1117/12.434744
Bargo, P. R. ; Jacques, Steven. / Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT. Proceedings of SPIE - The International Society for Optical Engineering. editor / D.D. Duncan ; S.L. Jacques ; P.C. Johnson. Vol. 4257 2001. pp. 50-56
@inproceedings{2a001ed05dee49b9839f980b4bc9d233,
title = "Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT",
abstract = "The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.",
keywords = "Dosimetry, Fluorescence, Optics, PDT, Photodynamictherapy, Reflectance",
author = "Bargo, {P. R.} and Steven Jacques",
year = "2001",
doi = "10.1117/12.434744",
language = "English (US)",
volume = "4257",
pages = "50--56",
editor = "D.D. Duncan and S.L. Jacques and P.C. Johnson",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",

}

TY - GEN

T1 - Clinical study assessing the photosensitizer accumulation and light penetration for esophageal cancer prior to treatment by PDT

AU - Bargo, P. R.

AU - Jacques, Steven

PY - 2001

Y1 - 2001

N2 - The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

AB - The FDA has approved PDT using Photofrin for certain esophageal and lung cancers, specifying an approved prescription of administered drug (mg/kg body weight) and administered light (J/linear cm of cylindrical fiber). This paper describes our development of a multi-optical fiber catheter for endoscopic use which documents the drug accumulated in the target tissues and the light penetration into the target tissues. The catheter uses reflectance to specify the light penetration depth and uses reflectance-corrected fluorescence to document drug accumulation. The goal is to document the variation in drug and light received by patients who are administered the FDA-approved prescription.

KW - Dosimetry

KW - Fluorescence

KW - Optics

KW - PDT

KW - Photodynamictherapy

KW - Reflectance

UR - http://www.scopus.com/inward/record.url?scp=0034877323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034877323&partnerID=8YFLogxK

U2 - 10.1117/12.434744

DO - 10.1117/12.434744

M3 - Conference contribution

VL - 4257

SP - 50

EP - 56

BT - Proceedings of SPIE - The International Society for Optical Engineering

A2 - Duncan, D.D.

A2 - Jacques, S.L.

A2 - Johnson, P.C.

ER -